Skip to main content
PMC home page
The British Journal of General Practice logoLink to The British Journal of General Practice
. 2003 Oct;53(495):772–777.

A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care.

Alan J Lenox-Smith 1, Alan Reynolds 1
PMCID: PMC1314709  PMID: 14601352

Abstract

BACKGROUND: Generalised anxiety disorder (GAD) is one of the commonest anxiety disorders and is treated almost entirely in primary care. Most recent studies performed in GAD have excluded depression for regulatory reasons. As GAD is usually a co-morbid disease, often co-existing with depression, the results from recent studies have only limited relevance to the naturalistic population. This study was set up to investigate venlafaxine XL in a more naturalistic population of patients with GAD. AIM: To assess the efficacy of venlafaxine XL in patients with generalised anxiety disorder with and without co-morbid depression. DESIGN OF STUDY: Double-blind, randomised, placebo controlled, parallel-group, 24-week study. SETTING: Primary care in the UK. METHODS: Patients enrolled in the study were over 18 years old, met DSM-IV criteria for GAD, and had a score of 20 or more on the Hamilton Anxiety Scale (HAM-A). A score of more than 23 on the Montgomery Asberg Depression Rating Scale (MADRS) excluded patients. Eligible patients were randomised to receive 75 mg of venlafaxine or a matching placebo. After 2 weeks the dose could be doubled if the physician considered the response to be poor. The study duration was 24 weeks. RESULTS: 244 patients were enrolled, with 122 randomised to the placebo and 122 to venlafaxine. Baseline characteristics were similar for both groups, each having a mean total HAM-A score at baseline of 28. The difference from the placebo group at 24 weeks on the total HAM-A score was 2.1 points (95% 0 to 4.2), which was statistically significant (P = 0.05). Remission rates at week 24 were 27.9% for the venlafaxine XL group and 18.9% for placebo group (P = 0.11). CONCLUSION: Venlafaxine was efficacious in the treatment of patients with GAD with and without depression over a 24-week period.

Full Text

The Full Text of this article is available as a PDF (82.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allgulander C., Hackett D., Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001 Jul;179:15–22. doi: 10.1192/bjp.179.1.15. [DOI] [PubMed] [Google Scholar]
  2. Allgulander C., Lavori P. W. Excess mortality among 3302 patients with 'pure' anxiety neurosis. Arch Gen Psychiatry. 1991 Jul;48(7):599–602. doi: 10.1001/archpsyc.1991.01810310017004. [DOI] [PubMed] [Google Scholar]
  3. Anderson D. J., Noyes R., Jr, Crowe R. R. A comparison of panic disorder and generalized anxiety disorder. Am J Psychiatry. 1984 Apr;141(4):572–575. doi: 10.1176/ajp.141.4.572. [DOI] [PubMed] [Google Scholar]
  4. Ansseau M., Olié J. P., von Frenckell R., Jourdain G., Stehle B., Guillet P. Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder. Psychopharmacology (Berl) 1991;104(4):439–443. doi: 10.1007/BF02245646. [DOI] [PubMed] [Google Scholar]
  5. Barlow D. H., Blanchard E. B., Vermilyea J. A., Vermilyea B. B., DiNardo P. A. Generalized anxiety and generalized anxiety disorder: description and reconceptualization. Am J Psychiatry. 1986 Jan;143(1):40–44. doi: 10.1176/ajp.143.1.40. [DOI] [PubMed] [Google Scholar]
  6. Davidson J. R., DuPont R. L., Hedges D., Haskins J. T. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999 Aug;60(8):528–535. doi: 10.4088/jcp.v60n0805. [DOI] [PubMed] [Google Scholar]
  7. Gelenberg A. J., Lydiard R. B., Rudolph R. L., Aguiar L., Haskins J. T., Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000 Jun 21;283(23):3082–3088. doi: 10.1001/jama.283.23.3082. [DOI] [PubMed] [Google Scholar]
  8. Jenkins R., Lewis G., Bebbington P., Brugha T., Farrell M., Gill B., Meltzer H. The National Psychiatric Morbidity surveys of Great Britain--initial findings from the household survey. Psychol Med. 1997 Jul;27(4):775–789. doi: 10.1017/s0033291797005308. [DOI] [PubMed] [Google Scholar]
  9. Kessler R. C., McGonagle K. A., Zhao S., Nelson C. B., Hughes M., Eshleman S., Wittchen H. U., Kendler K. S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994 Jan;51(1):8–19. doi: 10.1001/archpsyc.1994.03950010008002. [DOI] [PubMed] [Google Scholar]
  10. Lader M., Scotto J. C. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl) 1998 Oct;139(4):402–406. doi: 10.1007/s002130050731. [DOI] [PubMed] [Google Scholar]
  11. Lydiard R. B., Ballenger J. C., Rickels K. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry. 1997;58 (Suppl 11):11–18. [PubMed] [Google Scholar]
  12. Massion A. O., Warshaw M. G., Keller M. B. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry. 1993 Apr;150(4):600–607. doi: 10.1176/ajp.150.4.600. [DOI] [PubMed] [Google Scholar]
  13. Noyes R., Jr, Clarkson C., Crowe R. R., Yates W. R., McChesney C. M. A family study of generalized anxiety disorder. Am J Psychiatry. 1987 Aug;144(8):1019–1024. doi: 10.1176/ajp.144.8.1019. [DOI] [PubMed] [Google Scholar]
  14. Olfson M., Weissman M. M., Leon A. C., Sheehan D. V., Farber L. Suicidal ideation in primary care. J Gen Intern Med. 1996 Aug;11(8):447–453. doi: 10.1007/BF02599038. [DOI] [PubMed] [Google Scholar]
  15. Pollack M. H., Worthington J. J., Manfro G. G., Otto M. W., Zucker B. G. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry. 1997;58 (Suppl 11):19–23. [PubMed] [Google Scholar]
  16. Rickels K., Case G. W., Winokur A., Swenson C. Long-term benzodiazepine therapy: benefits and risks. Psychopharmacol Bull. 1984 Fall;20(4):608–615. [PubMed] [Google Scholar]
  17. Rickels K., Pollack M. H., Sheehan D. V., Haskins J. T. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000 Jun;157(6):968–974. doi: 10.1176/appi.ajp.157.6.968. [DOI] [PubMed] [Google Scholar]
  18. Rickels K., Schweizer E. The clinical course and long-term management of generalized anxiety disorder. J Clin Psychopharmacol. 1990 Jun;10(3 Suppl):101S–110S. [PubMed] [Google Scholar]
  19. Roemer L., Molina S., Borkovec T. D. An investigation of worry content among generally anxious individuals. J Nerv Ment Dis. 1997 May;185(5):314–319. doi: 10.1097/00005053-199705000-00005. [DOI] [PubMed] [Google Scholar]
  20. Yonkers K. A., Warshaw M. G., Massion A. O., Keller M. B. Phenomenology and course of generalised anxiety disorder. Br J Psychiatry. 1996 Mar;168(3):308–313. doi: 10.1192/bjp.168.3.308. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of General Practice are provided here courtesy of Royal College of General Practitioners

RESOURCES